Misoprostol Powder CAS 59122-46-2

The most well-known use in obstetrics and gynecology is sequential use with mifepristone to terminate early pregnancy within 49 days of amenorrhea. Mifepristone, as a progesterone receptor antagonist, can cause degeneration, necrosis, and detachment of embryonic villus tissue from the uterine wall. Subsequently, misoprostol was used, which binds to receptors on the uterine smooth muscle, triggering calcium ion influx and causing rhythmic strong contractions of the uterine smooth muscle.

At the same time, it softens cervical fibrous tissue, degrades collagen, and causes cervical dilation, thereby promoting the expulsion of embryonic tissue from the body. This medication abortion plan must be used under the guidance of trained doctors in medical institutions with emergency curettage surgery and infusion/transfusion conditions. After medication, it is necessary to closely observe the bleeding situation and whether the pregnancy is completely discharged.

Some users may experience adverse reactions such as abdominal pain, nausea, and diarrhea. About 80% of pregnant women excrete chorionic villi within 6 hours after taking misoprostol, and about 10% of pregnant women excrete pregnancy products within one week after taking the medication. If the abortion is incomplete or the pregnancy continues, timely treatment is necessary. If the termination of early pregnancy fails, artificial abortion must be performed to terminate the pregnancy.

Plays an important role in induced abortion during full-term pregnancy. For pregnant women in late pregnancy who need to terminate their pregnancy and have immature cervical conditions, misoprostol powder can mature the cervix and induce regular contractions, initiating the delivery process. It can cause cervical connective tissue to release proteases to hydrolyze collagen fibers, thereby softening the cervix and facilitating fetal delivery.

This use must be carried out under close supervision in the hospital, and evaluated by obstetricians based on the specific situation of the mother before use. The dosage of medication should be strictly controlled and the intensity of uterine contractions should be monitored to avoid the risks that may arise from excessive uterine contractions, such as serious complications such as uterine rupture. In addition, it can also be used for induced abortion of stillbirths and expired pregnancies, providing effective drug means to solve these abnormal pregnancy situations.

Postpartum hemorrhage is one of the serious complications during childbirth, and misoprostol has significant effects in preventing and treating postpartum hemorrhage caused by uterine atony. After the delivery of the fetus, immediate sublingual administration of misoprostol tablets can enhance uterine contractions and reduce the occurrence of postpartum bleeding. Its mechanism of action is to directly stimulate the contraction of uterine smooth muscle, shorten and widen uterine muscle fibers.

Reduce the volume of the uterine cavity, compress the blood sinuses, and stop bleeding. Compared with traditional oxytocin, it has the advantages of convenient use and no need for intravenous administration, especially suitable for primary medical units or situations where oxytocin is contraindicated. In clinical applications, it is often used in conjunction with oxytocin to enhance hemostatic effects and better ensure the safety of postpartum women's lives.

Before performing gynecological surgeries such as hysteroscopy, induced abortion, and curettage, using it can soften the cervix, reduce surgical difficulty and bleeding. Placing misoprostol tablets in the vagina can cause the cervical connective tissue to release proteases, hydrolyze collagen fibers, and soften and open the cervix after drug absorption. This makes it easier for instruments to enter the uterine cavity through the cervix during surgery, reducing mechanical damage to the cervix and lowering the risk of surgical complications such as cervical lacerations and uterine perforation.

It is an effective medication for treating duodenal ulcers and gastric ulcers, especially suitable for arthritis patients with ulcers caused by the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Long term or high-dose use of NSAIDs, such as ibuprofen, diclofenac sodium, etc., can inhibit the synthesis of prostaglandins in the gastric mucosa, weaken the defense ability of the gastric mucosa, and lead to gastric mucosal damage, erosion, and even ulcers. 

By inhibiting gastric acid secretion, reducing the stimulation and damage of gastric acid to the gastric mucosa, while increasing the blood flow and secretion of mucus and bicarbonate in the gastric mucosa, enhancing the barrier function of the gastric mucosa, and promoting ulcer healing. For NSAID related gastric ulcers that have already occurred, this drug can accelerate mucosal repair and alleviate pain symptoms. Most patients' ulcers can heal within 4 weeks, but if necessary, the treatment period can be extended to 8 weeks. If there is ulcer recurrence, a new course of treatment can be initiated.

For patients who require long-term use of NSAIDs, especially elderly patients or those with a history of ulcers, doctors may recommend the combination of misoprostol for prevention. It can reduce the risk of ulcers caused by NSAIDs and maintain the normal defense function of gastric mucosa.

Its preventive effect is based on its ability to inhibit gastric acid secretion and enhance the protective mechanism of the gastric mucosa, reducing the damage of gastric acid and other irritants to the gastric mucosa. Long term low-dose use of misoprostol powder can effectively prevent the recurrence of gastric or duodenal ulcers, improve patients' quality of life, and reduce hospitalization and surgical risks caused by ulcer complications.

Often used in combination with other medications to assist in the treatment of gastric diseases such as gastritis and gastroesophageal reflux disease. In the treatment of gastritis, it inhibits gastric acid secretion and protects the gastric mucosa, reducing the inflammatory response of the gastric mucosa and promoting its repair.

For gastroesophageal reflux disease, it can increase the blood flow in the submucosal layer of the stomach, promote mucosal repair, reduce the damage of gastric acid reflux to the esophageal mucosa, alleviate symptoms such as heartburn and acid reflux, shorten the course of the disease, and improve prognosis. Combined use with proton pump inhibitors, H ₂ receptor antagonists, and other drugs can enhance the comprehensive therapeutic effect on gastric diseases.

It can enhance the efficacy of certain drugs, such as when used in combination with analgesics, which can enhance the analgesic effect. Its mechanism of action may be related to its regulation of the levels of certain neurotransmitters or inflammatory factors in the body, by affecting the transmission and processing of pain signals, increasing the sensitivity of analgesics, and thus better alleviating pain symptoms. This combination therapy can provide patients with more effective pain management plans in clinical practice, especially suitable for the treatment of some chronic pain diseases.

Misoprostol can prevent and treat stress ulcers in severe trauma, major surgery, and other stressful situations. Under stress, the sympathetic nervous system of the body is stimulated, and the secretion of adrenal cortex hormones increases, which can lead to ischemia and hypoxia of the gastric mucosa, increased secretion of gastric acid, and thus trigger stress ulcers.

Misoprostol reduces the risk of stress ulcers and protects the gastric mucosa from damage caused by stress factors by inhibiting gastric acid secretion and enhancing gastric mucosal defense function. In addition, some studies have explored the potential applications of misoprostol in other fields, such as the treatment of chemotherapy-induced mucositis, but these applications are still in the research stage and require further clinical validation.